Retatrutide Advances in GLP-1 Obesity Drug Research for 2025 | Retatrutide News

Retatrutide is gaining attention in GLP-1 obesity drug research, with Eli Lilly leading efforts. The news highlights ongoing advancements but lacks spec...
Market News · October 26, 2026